Business
Emergent BioSolutions Announces Stock Repurchase Program
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026. “As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our investment priorities to remain focused on driving long-term growth and profitability,” said Joe Papa, president and CEO of Emergent. “This announcement ref
About this update from Emergent Biosolutions Inc.
[{"type":"image","alt":"Emergent BioSolutions","displaySize":"","headline":null,"caption":"Emergent BioSolutions","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8Cci..ShG_us_SMdQyxhzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d","width":300,"height":36}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026.","length":246,"tagName":"p"},{"type":"text","content":"“As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our investment priorities to remain focused on driving long-term growth and profitability,” said Joe Papa, president and CEO of Emergent. “This announcement reflects our confidence in the company’s strategy, future outlook and cash generation and provides another avenue for us to create long-term value for shareholders, while delivering on our mission to protect and save lives.”","length":474,"tagName":"p"},{"type":"text","content":"Stock repurchases under the newly authorized program may be made from time to time on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the company’s management based on its evaluation of market conditions and other factors, including the market price of the company’s common shares, macroeconomic environment and other investment opportunities, consistent with its insider trading policy. The repurchase program may be suspended or discontinued at any time.","length":535,"tagName":"p"},{"type":"text","content":"The company had approximately 54.3 million shares of common stock outstanding as of December 31, 2024.","length":102,"tagName":"p"},{"type":"text","content":"About Emergent BioSolutions","length":27,"tagName":"p"},{"type":"text","content":"At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and...